BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190318
DTEND;VALUE=DATE:20190320
DTSTAMP:20260514T223809
CREATED:20181022T121303Z
LAST-MODIFIED:20181022T121355Z
UID:18094-1552867200-1553039999@www.pharmajournalist.com
SUMMARY:21st Annual Superbugs & Superdrugs Conference
DESCRIPTION:As the global threat of antimicrobial resistance continues to grow\, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. \n \nSMi’s highly anticipated Superbugs & Superdrugs conference is set to return to London\, UK for its 21st year running\, on the 18th & 19th March 2019. This year’s event aims to provide valuable insights and key updates on the latest developments within the scientific communities\, as well as the processes and strategies pharmaceuticals use to develop novel therapeutics that utilise alternative mechanisms to treat multi-drug resistant infections. \nThe two-day conference will also host a diverse gathering of policy makers and economists\, in addition to big pharmas and biotechs\, who will discuss incentives\, partnerships\, regulations and new policies. Industry experts and scientific pioneers are set to present on their research advances and clinical data\, as well as alternatives to antibiotics\, such as monoclonal antibodies and antimicrobial peptides.  \n2019 HIGHLIGHTS:  \n\nAnalyse the current status of antimicrobial resistance with industry-led insight into current strategies to tackle AMR\nHear about novel immune-therapeutics to target Gram-negative bacterial infections\nLearn about strategies to combat β-lactamases\nEvaluate the development of precision antibiotics: Agents designed to meet the demands of stewardship\nExplore the role of plasmids in the evolution of antimicrobial resistance\n\nJoin us in London next year to explore the challenges and solutions to the growing threat of antibiotic resistance\, as well as take part in interactive roundtable discussions with leading organisations. Attendees will also have the exclusive opportunity of networking with an unrivalled gathering of senior experts from Chemical Biology Ventures\, University of Oxford\, MedImmune\, HPRA\, GARDP\, DNDi\, Bioharmony Therapeutics\, and many more.  \nEarly Bird Discounts!  \nBook by November 30th and save £400\nBook by December 14th and save £200\nBook by January 31st and save £100  \nFor more information and to register online\, please visit http://www.superbugssuperdrugs.com/pjwl
URL:https://www.pharmajournalist.com/event/21st-annual-superbugs-superdrugs-conference/
LOCATION:HOLIDAY INN KENSINGTON FORUM\, 97 Cromwell Road\, London\, SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:mmandic@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190318
DTEND;VALUE=DATE:20190320
DTSTAMP:20260514T223809
CREATED:20181029T164425Z
LAST-MODIFIED:20181029T164425Z
UID:18183-1552867200-1553039999@www.pharmajournalist.com
SUMMARY:3rd Annual Drug Discovery Chemistry
DESCRIPTION:SMi’s 3rd Annual Drug Discovery Chemistry  \nDeveloping your R&D pipeline with strategies to deliver small molecules  \nConference: 18 – 19 March 2019\nWorkshop: 20 March 2019\nLocation: Copthorne Tara Hotel\, London\, UK\nWebsite: www.drug-discovery.co.uk/PJwl \nCHAIRED BY: \nRoderick Hubbard\, Senior Fellow\, Vernalis Research Ltd\nDarren Green\, Director of Molecular Design\, GSK \nSMi is proud to present its 3rd Annual Drug Discovery Chemistry event\, taking place on the 18th-19th March 2019. \n \nThe fight to optimise the drug discovery process is on as there is currently a reduced output of new medicines within the market\, however\, demand for novel drugs is still steadily increasing.M \nThis year’s event will specifically focus on innovations within the field that has the potential to drive the pharmaceutical industry into a new era of medicines\, with optimization of the R&D process to become cheaper\, faster and increasing the likelihood of drug efficacy and success. These are some of the major obstacles within drug discovery at present\, as the process is overall long\, expensive and often potential drugs will fail late in clinical trials\, wasting resources and time. \nThe event will also focus on novel techniques that can be implemented within the field today that can identify new druggable targets and possibly open new therapeutic areas within the clinic. This could offer opportunities for pharmaceutical companies to produce medicines for diseases and ailments that have previously not been targeted\, and likewise\, offer new drug targets for existing diseases that could potentially offer better clinical outcomes\, such as within the development of cancer drugs. \nDrug Discovery Chemistry 2019 will look at various developments within the field\, guiding companies on how they can best utilize the newest technologies and drug discovery modalities to develop new medicines\, reduce their R&D cost and timelines\, and ultimately\, increase their medicine output for commercial success. \nEvent Hashtag: #SMiDrugDisChem \nKEY SPEAKERS INCLUDE: \n\nVivek Vishnudas\, Senior Vice President Drug discovery & Platform Sciences\, Berg LLC\nTobias Gabriel\, Global Head of Discovery Chemistry\, Novartis\nGovinda Bhisetti\, Principal Investigator and Head of Computational Chemistry\, Biogen\nHasane Ratni\, Expert Scientist\, F Hoffmann-La Roche\nAlexander Hillisch\, Director of Medicinal Chemistry\, Bayer \n\nKEY TOPICS FOR 2018 INCLUDE: \n\nDiscuss the impact of the use of novel computational techniques on R&D pipelines\nHear about the progress in the development of new drugs on difficult targets and how these can revolutionise patient treatment\nDiscover how AI is being utilised in the commercial setting and opportunities to best exploit these to streamline the Drug Discovery Process\nExplore the potential of new modalities to transform therapeutics\nLearn about current strategies to increase drug discovery success \n\nPost conference workshop on 20 March 2019 \nArtificial Intelligence in Drug Discovery \nLed by: Nick Camp\, Consultant \nWHO SHOULD ATTEND \nCEOs\, Presidents\, Vice Presidents and Global Heads\, Executive Directors\, Vice President & Global head\, Principal Scientists\, Heads of Business Development\, Directors of Pharma/Biotech firms. \nEARLY BIRD-RATES \n\nBOOK BY 30 NOVEMBER AND SAVE £400\nBOOK BY 15 DECEMBER AND SAVE £200\nBOOK BY 31 JANUARY AND SAVE £100
URL:https://www.pharmajournalist.com/event/3rd-annual-drug-discovery-chemistry/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Ltd.":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR